SC 101 - Tianjin ConjuStar Biologics
Alternative Names: SC-101 - Tianjin ConjuStar BiologicsLatest Information Update: 12 Mar 2024
At a glance
- Originator Tianjin ConjuStar Biologics
- Class Antineoplastics; Peptide drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 27 Feb 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in China (IV) (NCT06220838)
- 25 Jan 2024 Preclinical trials in Solid tumours in China (IV) prior to January 2024 (Tianjin ConjuStar Biologics pipeline, January 2024)
- 24 Jan 2024 Tianjin ConjuStar Biologics plans a phase-I trial for Solid tumours (Late-stage disease, Metastatic disease) in China (IV) (NCT06220838)